Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study. Issue 3 (23rd December 2016) - Pathmanathan, Nirmala
Abstract: Aim: Current estimates of the human epidermal growth factor receptor 2 (HER2)‐positivity rate in gastric cancer vary widely in the literature, and there are limited data from countries in Asia. The primary aim of this study was to conduct a clinical audit of laboratories across seven countries in Asia to determine the incidence of HER2‐positive gastric cancer in this region. Methods: Pathologists were asked to collect data on patient gender, age, cancer site, specimen type, tumor spread, type and grade, HER2 test results, including protein and/or gene copy enumeration, and final HER2 status on consecutive gastric cancer cases tested for HER2 in their laboratory over a 2‐year period. Results: HER2 results from 5, 301 gastric cancers were submitted by 50 laboratories. The overall HER2‐positivity rate was 9.7% which, after the exclusion of China, increased to 18.1%. The rate between countries ranged from 0% to 23.1%, and from 0% to 50.0% between laboratories. An equivocal HER2 result was recorded in 19.5% of cases. Conclusion: Despite the lack of centralized testing to confirm the accuracy of HER2 diagnoses, the incidence of HER2‐positive gastric cancer observed here was comparable to that reported in the literature. Nevertheless, rates were highly variable between countries and laboratories, which suggests a lack of HER2 testing expertise in gastric cancer. Given that the mortality rates for gastric cancer in Eastern Asia are the highest in the world, efforts should focus on improving HER2 testing expertise in the region so that patients receive the appropriate treatment early in their disease.